drugset / Trial / NCT02037984

Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004)

NCT02037984

Phase 1/2 Completed 341 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupTriple-blindPrevention

Summary

This study is designed to assess the safety, tolerability, and immunogenicity of 5 different formulations of V114 in healthy adults and infants. Adults only will be enrolled in Period 1 and infants only will be enrolled in Period 2; Period 1 will complete prior to the start of Period 2.

Timeline

Start
2014-01-28
Primary completion
2016-07-01
Completion
2016-07-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Prevnar 13 Vaccine
Subject V114 Vaccine